Phase 1 of EC1169 In Patients With Recurrent MCRPC
Status:
Completed
Trial end date:
2018-11-29
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety of EC1169 and the best dose to use in
humans in future studies. This study will also determine how EC1169 is distributed, broken
down, passed and absorbed through your body and how quickly it is eliminated (leaves the
body). All patients will receive EC1169.
As a secondary objective in Part A: To explore the relationships between baseline PSMA
expression (tumor and patient level) as measured by 99mTc-EC0652 scans and the antitumor
activity of EC1169.
As an exploratory objective in Part B: To assess EC0652 as a predictive biomarker for the
efficacy of EC1169 by comparing PSMA-positive and PSMA-negative lesions for response.